This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Verva Pharmaceuticals Ltd.
Drug Names(s): methazolamide
Description: VVP808 is a non-thiazolidinedione insulin sensitizer for use in the treatment of type 2 diabetes mellitus (T2DM). This drug is a carbonic anhydrase inhibitor that has been previously used for the treatment of glaucoma. However, its mechanism of action in insulin sensitization is unknown.
Since VVP808 is an approved drug and has off-target effects, the company is trying to identify precisely its mechanism for insulin sensitization (which appears to be primarily in the liver, related to glucose production) and develop more potent and specific drugs. They have identified some candidates which appear to have 10x more of an effect on maximal glucose production in liver cells.
The company does not plan to develop VVP808 in the US, but rather the novel compounds, but may develop it ex-US via as a specialty pharmaceutical with a development partner.
Additional information available to subscribers only: